$Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma$

Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma

We report a case of a 57-year-old woman with a history of multiple myeloma (MM) and light chain (AL) amyloidosis who presented due to worsening dyspnea on exertion. Her MM has been refractory to multiple chemotherapy regimens and two autologous bone marrow transplantation. Diagnostic evaluations inc...

Full description

Saved in:

Bibliographic Details
Main Authors:	Abdulbaril Olagunju, Chandana Shekar, Michael Morris, Anantharam Kalya, Farouk Mookadam, Samuel Unzek
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Case Reports in Cardiology
Online Access:	http://dx.doi.org/10.1155/2022/7846846
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
by: Pradyumna Agasthi, et al.
Published: (2018-01-01)

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
by: Evelyn Taiwo, et al.
Published: (2014-01-01)

Heart rhythm safety of the mononuclear cord blood stem cells transplantation in patients with refractory ischemic heart failure
by: O.Yu. Usenko, et al.
Published: (2016-09-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

A Novel Myosin Essential Light Chain Mutation Causes Hypertrophic Cardiomyopathy with Late Onset and Low Expressivity
by: Paal Skytt Andersen, et al.
Published: (2012-01-01)

Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies
by: Samuel Jaimez-Alvarado, et al.
Published: (2025-01-01)

Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland
by: Maria Kraj, et al.
Published: (2015-01-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Nationwide Outcomes of Heart Transplantation for Postpartum Cardiomyopathy
by: Ilias P. Doulamis, et al.
Published: (2025-01-01)

Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy
by: Katsuya Endo, et al.
Published: (2021-01-01)

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)

Elevated resting heart rate in adolescent men and risk of heart failure and cardiomyopathy
by: Martin Lindgren, et al.
Published: (2020-06-01)

Refractory cardiogenic shock in hypertrophic cardiomyopathy complicated by apical ballooning: A case report
by: Matej Strycek, et al.
Published: (2025-02-01)

Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
by: Muhammad Husnain, et al.
Published: (2016-01-01)

Ceruloplasmin and the Extent of Heart Failure in Ischemic and Nonischemic Cardiomyopathy Patients
by: Yifei Xu, et al.
Published: (2013-01-01)

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
by: Aaron Trando, et al.
Published: (2024-12-01)

Naringin prevents heart mitochondria dysfunction during diabetic cardiomyopathy in rats
by: Ilya Zavodnik, et al.
Published: (2025-01-01)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
by: Rūta Čepulytė, et al.
Published: (2020-01-01)

Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin.
by: Jahan Abdi, et al.
Published: (2025-01-01)

The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy
by: Vamsi C. Gaddipati, et al.
Published: (2017-01-01)

Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
by: Bhanu K. Patibandla, et al.
Published: (2014-01-01)

A Rare Case of Light Chain Amyloidosis of the Gastrointestinal Tract
by: Kathrin Dvir, et al.
Published: (2020-01-01)

Fabry cardiomyopathy: Gb3‐induced auto‐reactive panmyocarditis requiring heart transplantation
by: Andrea Frustaci, et al.
Published: (2020-06-01)

Impairment of myocardial perfusion correlates with heart failure severity in patients with non‐compaction cardiomyopathy
by: Andraz Cerar, et al.
Published: (2020-06-01)

Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
by: A. Visram, et al.
Published: (2023-12-01)

Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy
by: Brian P. Halliday, et al.
Published: (2022-06-01)

First Case Report of Arrhythmogenic Right Ventricular Cardiomyopathy Showing Refractory Ventricular Tachycardia Induced by Thyroid Storm due to Graves’ Disease
by: Masaki Matsubara, et al.
Published: (2022-01-01)

Prognostic correlation analysis of multiple myeloma based on HALP score of peripheral blood before chemotherapy
by: CHEN Min, et al.
Published: (2025-01-01)

The role of neurofilament light chain in the context of neurological disorders
by: V. Taluntienė, et al.
Published: (2020-12-01)

Amyloidogenic immunoglobulin light chains disturb contractile function and calcium transients in a human cardiac spheroid model of light chain (AL) amyloidosis
by: Mélanie Bézard, et al.
Published: (2025-02-01)

Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
by: Huamao Mark Lin, et al.
Published: (2019-01-01)

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
by: Lawrence G Lum, et al.
Published: (2025-01-01)

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
by: Inés Zugasti, et al.
Published: (2025-02-01)

Cirrhotic cardiomyopathy
by: S. N. Mammayev, et al.
Published: (2010-06-01)

Thromboprophylaxis in multiple myeloma
by: Laurent Frenzel
Published: (2025-01-01)

Multiple Myeloma of the Orbit
by: Mona Hassan, et al.
Published: (2012-01-01)

Kansas City Cardiomyopathy Questionnaire Utility in Prediction of 30-Day Readmission Rate in Patients with Chronic Heart Failure
by: Shengchuan Dai, et al.
Published: (2016-01-01)

The Correlation of PPARα Activity and Cardiomyocyte Metabolism and Structure in Idiopathic Dilated Cardiomyopathy during Heart Failure Progression
by: E. Czarnowska, et al.
Published: (2016-01-01)

Successful Long-Term Use of Eltrombopag in a Patient with Refractory Severe Thrombocytopenia Associated with Chronic Lymphocytic Leukemia That Allowed Oral Anticoagulant Treatment for Severe Cardiomyopathy
by: Juárez Salcedo Luis Miguel, et al.
Published: (2017-01-01)

Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition
by: Varinder K. Randhawa, et al.
Published: (2020-06-01)